5/9/2012
Courtagen Submits Pre-IDE Information Package for the Avantra® Q400 Workstation and QPDx® BioChip
Courtagen Life Sciences, Inc., a privately held life sciences company that provides innovative proteomic and genomic products and services to the life sciences industry, today announced that the company has submitted its first pre- IDE (Investigational Device Exemption) information package to the U.S. Food and Drug Administration for the Company’s Avantra® Q400 BioMarker Workstation and QPDX® BioChip for the measurement of C-reactive protein (CRP). Courtagen is also pursuing a CE Mark Approval for the European Union.
|
|
3/29/2012
Courtagen Introduces Genomic Profiling Services in their Newly Licensed CLIA Lab
Courtagen Life Sciences, Inc.announced today the introduction of their first genetic tests using next
generation sequencing (NGS) technology, propriety bioinformatics platform and highly annotated, analytic capabilities to diagnose mitochondrial disease in children and adults. The Courtagen tests, which are designed to be highly sensitive, efficient and comprehensive, will address the significant need for a quicker, less invasive and more reliable diagnostic tool for this patient population.
|
|
2/29/2012
Courtagen to Partner with Avaxia Biologics in GI Acute Radiation Syndrome Initiative
Courtagen Life Sciences, Inc. (“Courtagen”), a privately held life sciences company that provides innovative proteomic and genomic products and services to the life sciences industry, today announced that it has entered into a strategic collaboration with Avaxia Biologics, Inc. (“Avaxia”) to develop an assay that will streamline the development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident. The combined effort will focus on addressing the critical need to quickly and accurately identify the impact of Avaxia’s oral antibody therapy in animal models and, ultimately, in patients.
|
|
|
|
2/2/2012
Courtagen Life Sciences Recognized for New Product Innovation
Based on its recent analysis of the clinical diagnostic tools market, Frost & Sullivan recognizes Courtagen Life Sciences, Inc. with the 2011 North American Frost & Sullivan Award for New Product Innovation. Courtagen’s unique biomarker workstation platform, the Avantra® Q400, is intuitively designed and meets the need for a compact, highly sensitive, low-density multiplexed protein analysis system for research and clinical settings. This platform possesses several advantages for clinical laboratories, allowing clinicians to generate results quickly while keeping the chain of custody clear and simple.
|
|
1/18/2012
Courtagen Appoints Kevin McKernan CSO
Courtagen Life Sciences, Inc. (“Courtagen”), a privately held life sciences company that provides innovative proteomic and genomic products and services to the life sciences industry, announced today that it has appointed Kevin McKernan Chief Scientific Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
